CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset ","$":{"href":"/biotech/gsk-pens-13b-hutchmed-deal-early-stage-kras-egfr-cancer-asset","hreflang":"en"}}]}

Positive
AI Analysis

Summary

GSK acquires Hutchmed's first-in-class KRAS-EGFR cancer asset for $110 million upfront with total deal value up to $1.295 billion.

Importance:7/10
Sentiment:
0.60
M&Aoncologyearly-stageKRASEGFRfirst-in-class
Related Companies

Read the original article

Published by FierceBiotech on September 3, 2026 5:07 AM

Read Original